Stephen J.LurieMD, PhD, Senior EditorJody W.ZylkeMD, Contributing Editor
To the Editor: In their Research Letter about industry sponsorship of grand rounds, Dr Dieperink and Ms Drogemuller1 suggest "that the increase in quetiapine fumarate prescriptions was influenced" by a grand rounds sponsored by the manufacturer. However, they do not prove that this increase was due to the meeting or its sponsorship.
While the authors list several caveats to their study, they do not discuss 3 additional methodological questions. First, was the increase in the prescribing of the sponsor's drug significantly greater for prescribers who attended the meeting vs those who did not? The authors could have determined this as they "had data about prescribing behavior at the individual level." Second, was any prescribing increase noted for drugs featured in the 51 nonsponsored meetings vs those not featured at their institution? Third, was there a significant difference in the prescribing increase for drugs featured in the 20 industry-sponsored meetings vs the 51 nonsponsored meetings? The authors could have answered these questions because they "looked at the content and sponsorship of all presentations" and had a "closed panel of prescribers."
Lohiya G. Effects of Industry Sponsorship of Grand Rounds. JAMA. 2001;286(8):917-918. doi:10.1001/jama.286.8.917-JLT0822-4-1